The ELISpot assay showed that when compared with CINS patients, stimulated PBMCs from COVID-19 patients will only activate approximately half the number of IFN-ɣ–producing lymphocytes (P < 0.0001). The gene discussed is IFNA1; the disease is COVID-19.